Humacyte, Inc. (NASDAQ:HUMA) Position Increased by Barclays PLC

Barclays PLC boosted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA) by 177.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 236,742 shares of the company’s stock after acquiring an additional 151,458 shares during the quarter. Barclays PLC owned 0.19% of Humacyte worth $1,288,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. State Street Corp grew its position in Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after acquiring an additional 1,895,529 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after buying an additional 1,334,641 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after buying an additional 524,600 shares during the period. Marshall Wace LLP grew its stake in Humacyte by 3,301.5% in the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after buying an additional 450,031 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new position in Humacyte in the 2nd quarter worth $1,550,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Insiders Place Their Bets

In other news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares in the company, valued at $7,615,889.60. This trade represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock valued at $6,606,799 in the last 90 days. 11.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on HUMA. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. Benchmark raised their price objective on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, December 23rd. D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Friday, December 20th. TD Cowen reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Trading Down 1.5 %

NASDAQ HUMA opened at $4.61 on Monday. Humacyte, Inc. has a 52 week low of $2.48 and a 52 week high of $9.97. The stock’s 50 day moving average price is $4.67 and its two-hundred day moving average price is $5.69. The stock has a market capitalization of $580.21 million, a price-to-earnings ratio of -3.44 and a beta of 1.32. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.